Clinical Trials List
2017-02-01 - 2021-12-27
Phase III
Terminated4
ICD-10C61
Malignant neoplasm of prostate
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- CHUNG-HSIN CHEN Division of Urology
- JHE-CYUAN GUO Division of Hematology & Oncology
- - - Division of Urology
- Ying-Chun Shen Division of Hematology & Oncology
- Yu-Chieh Tsai Division of Hematology & Oncology
- CHING-CHU LU Division of Nuclear Medicine
- YU-CHUAN LU Division of Urology
- YEN-HENG LIN Division of Radiology
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Co-Principal Investigator
- 朱力行 Division of Nuclear Medicine
- Yen-Hwa Chang Division of Urology
- 沈書慧 Division of Radiology
- Tzu-chun Wei Division of Urology
- Tzu-Ping Lin Division of Urology
- Yi-Hsiu Huang Division of Urology
- 潘競成 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 熊小澐 Division of Radiology
- Chuan-Shu Chen Division of Urology
- 蔡世傳 Division of Nuclear Medicine
- Cheng-Kuang Yang Division of Urology
- Cheng-Che Chen Division of Urology
- 裘坤元 Division of Urology
- Jian-Ri Li Division of Urology
The Actual Total Number of Participants Enrolled
0 Terminated
Taiwan National PI
Co-Principal Investigator
- Rita cheng Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- 劉忠一 Division of Hematology & Oncology
- 張英勛 Division of Hematology & Oncology
- Feng-Yuan Liu Division of Nuclear Medicine
- See-Tong Pang Division of Hematology & Oncology
- 黃成之 Division of Radiology
The Actual Total Number of Participants Enrolled
7 Terminated
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
29 participants
-
Global
730 participants
